Compare Barclays PLC (BCS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barclays PLC vs Sanofi SA — how do they compare? Barclays PLC trades at $28.11 (market cap $93.87B), while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Barclays PLC and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| BCS | SNY | |
|---|---|---|
Market Cap | $93.87B | $104.30B |
Sector | Financials | Health |
52-Week High | $28.56 | $52.34 |
52-Week Low | $19.36 | $41.33 |
Dividend Yield | 2.19% | 5.55% |
Enterprise Value | — | $124.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barclays PLC (BCS) trades at $28.09, up 0.39% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows a low P/E of 10.68 and P/B of 0.88, indicating potential undervaluation. Revenue grew to $29.14B in 2025, with net income margin at 25.51%, though cash flow volatility from 2023-2024 remains a concern. Recent news highlights a securities investigation and mixed analyst views post-Q2 results.
Outlook is cautiously optimistic due to valuation appeal and earnings strength, but risks include legal scrutiny and cost pressures. Analyst consensus is 68% buy, with sentiment tempered by near-term headwinds. The stock offers value if operational efficiency improves, yet investors should monitor the class-action probe and expense trends.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
